2 results
Approved WMOCompleted
Primary objective:The primary objective is the difference between the gammaCore®-R and the sham treatment groups in mean reduction in number of episodic migraine days during the last four weeks in the twelve-week randomized period compared with the…
Approved WMOCompleted
To demonstrate superiority with regard to Progression Free Survival based on an Independent Review Committeeassessment of avelumab versus platinum-based doublet in NSCLC subjects with PD-L1+